Method for treating cancer using chemokine antagonists
What is described is a method for treating cancer in a patient assaying levels of (a) CXCR1 and/or CXCR2 ligands or (b) myeloid derived suppressor cells (MDSCs) and/or neutrophils in the patient, and if the patient has increased levels of (a) or (b), then administering a therapeutically effective amount of a compound having a structure selected from the group consisting of formulas SX-517, SX-576, and SX-682
1. A method for treating a patient with a cancer, comprising assaying levels of (a) CXCR1 and/or CXCR2 ligands or (b) myeloid-derived suppressor cells (MDSCs) and/or neutrophils in a patient with a cancer, and if the patient has increased levels of (a) or (b), wherein the increased levels are caused by the cancer, then administering a pharmaceutical composition comprising a therapeutically effective amount of a compound having a structure selected from the group consisting of formulas SX-517, SX-576, and SX-682,
or a pharmaceutically acceptable salt or solvate thereof.
2. The method of claim 1 , further comprising administering an anticancer therapy.
3. The method of claim 2 , wherein the anticancer therapy is a chemotherapy.
4. The method of claim 2 , wherein carboplatin is administered to the patient.
5. The method of claim 2 wherein said anticancer therapy is radiation therapy.
6. The method of claim 1 wherein the compound has the structure of formula SX-682 and the cancer is selected from cancers of the prostate, colorectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head, neck, skin, mesothelial lining, blood, esophagus, breast, muscle, connective tissue, lung, adrenal gland, thyroid, kidney, lymphoid system, bone marrow or bone, glioblastoma, mesothelioma, renal cell carcinoma, gastric carcinoma, sarcoma, choriocarcinoma, cutaneous basocellular carcinoma, and testicular seminoma.
7. The method of claim 1 wherein the compound has the structure of formula SX-682 and the cancer is selected from cancers of the prostate, pancreas, stomach, brain, liver, head, neck, skin, blood, breast, lung, glioblastoma, and mesothelioma.
8. The method of claim 1 wherein the compound has the structure of formula SX-682 and the cancer is breast cancer.
9. The method of claim 8 , wherein the pharmaceutical composition is administered orally.
10. The method of claim 9 , further comprising administering a platinum chemotherapy.
11. The method of claim 1 wherein the compound has the structure of formula SX-682 and the cancer is a melanoma.
12. The method of claim 11 , wherein the pharmaceutical composition is administered orally.
13. The method of claim 12 , further comprising administering a platinum chemotherapy.
14. The method of claim 1 , wherein the cancer is a lung cancer.
15. The method of claim 14 , wherein the pharmaceutical composition is administered orally.
16. The method of claim 1 wherein the compound has the structure of formula SX-682 and the cancer is a prostate cancer.
17. The method of claim 16 , wherein the pharmaceutical composition is administered orally.
18. The method of claim 1 , wherein the cancer is a glioblastoma.
19. The method of claim 18 , wherein the pharmaceutical composition is administered orally.
20. The method of claim 19 , further comprising administering temozolomide.
21. The method of claim 1 , wherein the cancer is a pancreatic cancer.
22. The method of claim 21 , wherein the pharmaceutical composition is administered orally.
23. A method for treating a cancer, comprising administering to a patient with the cancer and with an increased level of (a) CXCR1 and/or CXCR2 ligands or (b) myeloid-derived suppressor cells (MDSCs) and/or neutrophils, wherein the increased levels are caused by the cancer, a pharmaceutical composition comprising a therapeutically effective amount of a dual CXCR1/2 antagonist selected from the group consisting of formulas SX-517, SX-576, and SX-682,
or a pharmaceutically acceptable salt or solvate thereof.
24. The method of claim 23 , further comprising administering an anticancer therapy.
25. The method of claim 24 , wherein the anticancer therapy is a chemotherapy.
26. The method of claim 25 , wherein the chemotherapy includes the step of administering carboplatin to the patient.
27. The method of claim 24 , wherein the anticancer therapy is radiation therapy.
28. The method of claim 23 , wherein the dual CXCR1/2 antagonist is navarixin and the cancer is selected from cancers of the prostate, colorectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head, neck, skin, mesothelial lining, blood, esophagus, breast, muscle, connective tissue, lung, adrenal gland, thyroid, kidney, lymphoid system, bone marrow or bone, glioblastoma, mesothelioma, renal cell carcinoma, gastric carcinoma, sarcoma, choriocarcinoma, cutaneous basocellular carcinoma, and testicular seminoma.
29. The method of claim 28 , further comprising administering a platinum chemotherapy.
30. The method of claim 29 , further comprising administering temozolomide.
31. The method of claim 23 , wherein the pharmaceutical composition is administered orally.